HLA-mismatched renal transplantation without maintenance immunosuppression - PubMed (original) (raw)
. 2008 Jan 24;358(4):353-61.
doi: 10.1056/NEJMoa071074.
A Benedict Cosimi, Thomas R Spitzer, Nina Tolkoff-Rubin, Manikkam Suthanthiran, Susan L Saidman, Juanita Shaffer, Frederic I Preffer, Ruchuang Ding, Vijay Sharma, Jay A Fishman, Bimalangshu Dey, Dicken S C Ko, Martin Hertl, Nelson B Goes, Waichi Wong, Winfred W Williams Jr, Robert B Colvin, Megan Sykes, David H Sachs
Affiliations
- PMID: 18216355
- PMCID: PMC2819046
- DOI: 10.1056/NEJMoa071074
HLA-mismatched renal transplantation without maintenance immunosuppression
Tatsuo Kawai et al. N Engl J Med. 2008.
Abstract
Five patients with end-stage renal disease received combined bone marrow and kidney transplants from HLA single-haplotype mismatched living related donors, with the use of a nonmyeloablative preparative regimen. Transient chimerism and reversible capillary leak syndrome developed in all recipients. Irreversible humoral rejection occurred in one patient. In the other four recipients, it was possible to discontinue all immunosuppressive therapy 9 to 14 months after the transplantation, and renal function has remained stable for 2.0 to 5.3 years since transplantation. The T cells from these four recipients, tested in vitro, showed donor-specific unresponsiveness and in specimens from allograft biopsies, obtained after withdrawal of immunosuppressive therapy, there were high levels of P3 (FOXP3) messenger RNA (mRNA) but not granzyme B mRNA.
Copyright 2008 Massachusetts Medical Society.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures
Figure 1. Clinical Course of Patients with Tolerance of Kidney Transplants
In Panel A, the serial creatinine levels in Patients 1, 2, 4, and 5 are indicated in yellow, and the withdrawal of immunosuppressive medications is shown as tapering bars above each creatinine curve. Arrows indicate the time at which allograft-biopsy specimens were obtained from these four patients. To convert the values for creatinine to micromoles per liter, multiply by 88.4. Panel B shows the recent protocol biopsy specimens from each of these four patients (obtained on days 1135, 1087, 731, and 666, respectively) (periodic acid–Schiff). The findings in all of the specimens were within normal limits, except for the specimen from Patient 4, which showed segmental glomerular basement membrane duplication and C4d deposition (see Fig. 1 in the Supplementary Appendix for representative glomeruli from protocol biopsy specimens).
Figure 2. In Vitro Assays for Tolerance of Kidney Transplantation
Sequential cell-mediated lympholysis assays in each patient against the donor (black circles) and third-party persons (gray circles) showed specific unresponsiveness to the donor at most post-transplantation time points tested (Panel A). Sequential assays of mixed-lymphocyte reactions in each patient against the donor (dark-blue bars) and third-party persons (light-blue bars) showed specific unresponsiveness to the donor, as indicated by return of anti–third-party, but not antidonor, responses after discontinuation of immunosuppressive therapy (Panel B). Arrows indicate the time of complete discontinuation of immunosuppressive therapy. Panel C shows intragraft levels of mRNA in renal allografts. Total RNA was isolated from renal-allograft biopsy specimens and reverse transcribed to cDNA, and levels of mRNA were measured with the use of preamplification enhanced real-time quantitative polymerase-chain-reaction assays. A total of 23 biopsy specimens were examined for intragraft levels of FOXP3 mRNA, granzyme B mRNA, and housekeeping gene 18S ribosomal RNA (18S rRNA). Of the 23 biopsy specimens, 6 were obtained from four patients with stable renal-allograft function who were not receiving immunosuppressive therapy (IS) (stable IS-free group). Eight biopsy specimens were obtained from eight patients with stable renal-allograft function and normal protocol biopsy results; these patients were receiving maintenance immunosuppressive drug therapy comprising tacrolimus and mycophenolate mofetil (stable-with-IS group). Five biopsy specimens were obtained from five kidney donors (normal-kidney group), and four biopsy specimens were obtained from four patients with biopsy-confirmed acute rejection (acute-rejection group). The mRNA copies were normalized with the use of 18S rRNA copies and log-transformed. The log-transformed mean (±SE) ratio of FOXP3 mRNA copies to 18S rRNA copies was 5.48±0.31 in the stable IS-free group, 3.90 ±0.27 in the stable-with-IS group, 2.85±0.34 in the normal-kidney group, and 7.09±0.38 in the acute-rejection group. The log-transformed mean ratio of granzyme B to 18S rRNA was 5.12±0.69 in the stable IS-free group, 4.53±0.59 in the stable-with-IS group, 3.41±0.75 in the normal-kidney group, and 9.76±0.84 in the acute-rejection group. Pre denotes pretransplantation.
Comment in
- Immunosuppressive therapy and tolerance of organ allografts.
Starzl TE. Starzl TE. N Engl J Med. 2008 Jan 24;358(4):407-11. doi: 10.1056/NEJMe0707578. N Engl J Med. 2008. PMID: 18216363 Free PMC article. No abstract available.
Similar articles
- Tolerance and chimerism after renal and hematopoietic-cell transplantation.
Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S. Scandling JD, et al. N Engl J Med. 2008 Jan 24;358(4):362-8. doi: 10.1056/NEJMoa074191. N Engl J Med. 2008. PMID: 18216356 - Clinical strategy for induction of transplantation tolerance through mixed chimerism.
Cosimi AB, Sachs DH, Sykes M, Kawai T. Cosimi AB, et al. Clin Transpl. 2013:127-34. Clin Transpl. 2013. PMID: 25095501 - Allogeneic hematopoietic stem-cell transplantation, mixed chimerism, and tolerance in living related donor renal allograft recipients.
Trivedi HL, Vanikar AV, Modi PR, Shah VR, Vakil JM, Trivedi VB, Khemchandani SI. Trivedi HL, et al. Transplant Proc. 2005 Mar;37(2):737-42. doi: 10.1016/j.transproceed.2005.01.028. Transplant Proc. 2005. PMID: 15848518 Clinical Trial. - Tolerance induction: hematopoietic chimerism.
Kawai T, Sachs DH. Kawai T, et al. Curr Opin Organ Transplant. 2013 Aug;18(4):402-7. doi: 10.1097/MOT.0b013e328363621d. Curr Opin Organ Transplant. 2013. PMID: 23838644 Review. - Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism.
Kawai T, Cosimi AB, Sachs DH. Kawai T, et al. Curr Opin Organ Transplant. 2011 Aug;16(4):366-71. doi: 10.1097/MOT.0b013e3283484b2c. Curr Opin Organ Transplant. 2011. PMID: 21666482 Free PMC article. Review.
Cited by
- Chimerism-Mediated Tolerance in Intestinal Transplantation.
Crosby K, Long KD, Fu J. Crosby K, et al. Gastroenterol Clin North Am. 2024 Sep;53(3):413-430. doi: 10.1016/j.gtc.2023.12.009. Epub 2024 Jan 16. Gastroenterol Clin North Am. 2024. PMID: 39068003 Review. - Combination cell therapy leads to clonal deletion of donor-specific T cells in kidney transplant recipients.
David AF, Heinzel A, Kammer M, Aschauer C, Reindl-Schwaighofer R, Hu K, Chen HS, Muckenhuber M, Kubetz A, Weijler AM, Worel N, Edinger M, Berlakovich G, Lion T, Sykes M, Wekerle T, Oberbauer R. David AF, et al. EBioMedicine. 2024 Aug;106:105239. doi: 10.1016/j.ebiom.2024.105239. Epub 2024 Jul 13. EBioMedicine. 2024. PMID: 38996766 Free PMC article. Clinical Trial. - Cellular strategies to induce immune tolerance after liver transplantation: Clinical perspectives.
Zhou AW, Jin J, Liu Y. Zhou AW, et al. World J Gastroenterol. 2024 Apr 7;30(13):1791-1800. doi: 10.3748/wjg.v30.i13.1791. World J Gastroenterol. 2024. PMID: 38659486 Free PMC article. Review. - Tolerance in intestinal transplantation.
Sykes M. Sykes M. Hum Immunol. 2024 May;85(3):110793. doi: 10.1016/j.humimm.2024.110793. Epub 2024 Apr 5. Hum Immunol. 2024. PMID: 38580539 Review. - Differentiation of regulatory myeloid and T-cells from adult human hematopoietic stem cells after allogeneic stimulation.
Mathew JM, Sanders JM, Cirocco R, Miller J, Leventhal JR. Mathew JM, et al. Front Immunol. 2024 Feb 22;15:1366972. doi: 10.3389/fimmu.2024.1366972. eCollection 2024. Front Immunol. 2024. PMID: 38455047 Free PMC article.
References
- Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580–90. - PubMed
- Sayegh MH, Carpenter CB. Transplantation 50 years later — progress, challenges, and promises. N Engl J Med. 2004;351:2761–6. - PubMed
- Murray JE, Merrill JP, Dammin GJ, et al. Study on transplantation immunity after total body irradiation: clinical and experimental investigation. Surgery. 1960;48:272–84. - PubMed
- Barber WH, Mankin JA, Laskow DA, et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation. 1991;51:70–5. - PubMed
- Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation. 2002;73:1386–91. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01 AI015416/AI/NIAID NIH HHS/United States
- R01 AI037692-09/AI/NIAID NIH HHS/United States
- R01 AI037692-10/AI/NIAID NIH HHS/United States
- R21 AI037692/AI/NIAID NIH HHS/United States
- R01 AI037692/AI/NIAID NIH HHS/United States
- U19 AI102405/AI/NIAID NIH HHS/United States
- N01AI15416/AI/NIAID NIH HHS/United States
- R21 AI037692-06/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials